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Abstract: Vaccine delivery using microneedles (MNs) represents a safe, easily 
disposable and painless alternative to traditional needle immunizations. The MN delivery 
of DNA vaccines to the dermis may result in a superior immune response and/or an 
equivalent immune response at a lower vaccine dose (dose-sparing). This could be of 
special interest for immunization programs against neglected tropical diseases such as 
 leishmaniasis. In this work, we loaded a MN device with 60 μg of a plasmid DNA cocktail 
encoding the Leishmania infantum nucleosomal histones H2A, H2B, H3 and H4 and 
compared its immunogenicity and protective capacity against conventional s.c. or i.d. 
injection of the 
plasmid. Mice immunized with MNs showed increased ratios of IFN-γ/IL-10, 
 IFN-γ/IL-13, IFN-γ/IL-4, and IFN-γ/TGF-β in the spleens and lymph nodes compared with 
mice immunized by s.c. and i.d. routes. Furthermore, CCXCL9, CXCL10 and CCL2 levels 
were also higher. These data suggest that the nucleic acid immunization using MNs 
produced a better bias towards a 
Th1 response. However, none of the immunizations strategies were able to control 
Leishmania major infection in BALB/c mice, as illustrated by an increase in lesion size 
and parasite burden. 
 
Keywords: Microneedle, skin vaccine delivery, DNA vaccine, histone, Leishmania 
1. Introduction 
Leishmaniasis is an infectious disease caused by protozoan parasite species of the genus 
Leishmania. This disease is one of the six major tropical diseases classified by the World Health 
Organization. Approximately, one billion people are at risk of infection worldwide and more than 
1.3 million new infections occur each year (Alvar et al., 2012). Depending on the species, 
Leishmania can cause visceral leishmaniasis (VL), which is fatal if untreated, or cutaneous 
leishmaniasis (CL). Current treatments are expensive, toxic and do not prevent disease relapse. 
Drug resistance is also increasing (Akbari et al., 2017). However, people previously infected 
with Leishmania can gain resistive immunity to reinfection and therefore the development and 
delivery of anti-leishmanial vaccines could be an effective means of controlling or eliminating CL 
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or VL (Gillespie et al., 2016). Although great efforts have been made in this area, there is still no 
effective vaccine against human leishmaniasis (Costa et al., 2011).  
In recent decades, potential candidate antigens such as killed and lived attenuated parasites, 
crude parasites, pure or recombinant Leishmania spp. proteins, DNA encoding leishmanial 
proteins or immunomodulators from sand fly saliva have been tested in animal models, but very 
few candidate vaccines have progressed beyond the experimental stage (Badiee et al., 2013; 
Jain and Jain, 2015; Khamesipour et al., 2006; Srivastava et al., 2016). DNA vaccines have 
numerous advantages over other vaccine strategies: (i) simple and cheap to produce, (ii) 
enhanced temperature stability, (iii) concurrent expression of multiple proteins in vivo, which are 
folded and modified in a comparable manner  to their corresponding native proteins, and (iv) 
ability to elicit Th1 responses and induce both CD4+ and CD8+ T cells, which is necessary for 
parasite eradication (Cui, 2005; Kumar and Samant, 2016). A variety of antigens have been 
studied as DNA vaccine expression products against Leishmania spp. including gp63 
(Mazumder et al., 2011), LACK (Ramos et al., 2008), CP-Ldccys1 (Ferreira et al., 2008), ORF 
(Sukumaran et al., 2003), KMP-11 (Guha et al., 2013), LiPABPs (Soto et al., 2015), LiP0 
(Pereira et al., 2015) and LEISHDNAVAX (Das et al., 2014). Whilst varying degrees of efficacy 
have been demonstrated in animal models, the level of protection elicited by DNA vaccines 
improves when multiple antigens are co-administered.  
There are five main classes of histones and four of them, H2A, H2B, H3 and H4, form the 
nucleosomal unit core of chromatin. Several studies suggest that Leishmania spp. histones are 
immunologically important during leishmaniasis (Baharia et al., 2014; Chenik et al., 2006; de 
Carvalho et al., 2003), making them attractive targets in the development of Leishmania spp. 
vaccines. Moreover, it is also known that Leishmania spp. histones are highly conserved 
between different species (Iborra et al., 2004). Studies carried out with these histones of L. 
infantum concluded that the combination of the four nucleosomal histones, expressed via a 
DNA vaccine, provided stronger immunity than separate or paired histone immunizations. This 
study also revealed that the DNA cocktail maintained protection against L. major reinfection 
(Carrion et al., 2008b). This plasmid DNA cocktail resulted in a specific Th1 response with 
enhanced IFN- γ production and low IL-4 levels, which contributed to control L. major infection in 
immunized mice (Iborra et al., 2004). Carneiro et al. also determined that BALB/c mice 
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immunized with the plasmid DNA mixture expressing four different L. infantum chagasi 
nucleosomal histones (homologous immunization, DNA/DNA) was as effective as the 
combination of the DNA cocktail followed by the corresponding recombinant proteins and CpG 
as an adjuvant (heterologous vaccination, DNA/rprotein+CpG) (Carneiro et al., 2012). 
Furthermore, HISA70, a DNA vaccine composed of the Leishmania spp. histones (H2A, H2B, 
H3 and H4), A2 and HSP70, was able to shift the response away from the more undesirable 
Th2 pathway, producing high levels of IL-17 and IFN-γ in vaccinated mice. These observations 
correlated with a complete absence of parasites in spleens after L. major infection (Dominguez-
Bernal et al., 2012). 
DNA vaccines provide promising candidates in the pursuit of new vaccines against Leishmania 
spp. In most cases these vaccines have been administered by the intramuscular (i.m.) or 
subcutaneous (s.c.) route. However, intradermal (i.d.) vaccination may provide an opportunity to 
increase the immunogenicity of DNA vaccines (Engelke et al., 2015). Muscle and subcutaneous 
tissue contains relatively few dendritic cells (DCs) compared to the dermis and epidermis of 
skin, which are densely populated by different subsets of DCs. These competent antigen 
presenting cells (APCs) play a central role in developing adaptive immune responses 
(Banchereau and Steinman, 1998), undoubtedly important in Leishmania spp. infection control. 
The delivery of DNA vaccines to the dermis may therefore result in a superior immune response 
and/or an equivalent immune response at a lower vaccine dose (dose-sparing) (Kenney et al., 
2004; Van Damme et al., 2009). Dose-sparing and the resulting reduction in unit costs could be 
of special interest for immunization programs in resource-poor areas. 
Currently, the Mantoux method is the conventional technique for i.d. vaccination. This 
technique, used for tuberculosis and rabies immunization, involves insertion of a hypodermic 
needle into the skin at an acute angle. It is painful and administration requires trained 
healthcare personnel (Scheiblhofer et al., 2013). Furthermore, the reuse of contaminated 
needles is a risk, particularly where their supply is short. The introduction of minimally-invasive 
microneedle (MN) devices may confer a number of advantages for i.d. injection: (i) ease of use 
and disposal, (ii) painless administration, (iii) reduced risk of infection through minimal blood 
contact, and (iv) potential for self-administration by patients (Larraneta et al., 2016). In addition, 
simultaneous delivery of antigen at multiple skin sites using MN arrays could result in effective 
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distribution of vaccines, leading to superior immune responses (Fehres et al., 2013). The 
coating of therapeutic antigen onto the outer surface MNs has been successfully used for 
vaccination purposes (Larraneta et al., 2016). Antigen delivery is achieved by diffusion of the 
antigen from the MN surface following their insertion into the skin, depositing the payload to a 
depth determined by the MN length and application process (Bal et al., 2010). Silicon MNs 
coated with a vaccine against malaria showed an efficacy comparable to conventional i.d. 
injection after challenge with live Plasmodium berghei sporozoites (Pearson et al., 2015). Kim et 
al. revealed that a single dose of an influenza vaccine coated onto stainless steel MNs 
produces superior immune response compared to i.m. vaccination (Kim et al., 2010). More 
recently, a solid MN patch coated with influenza virus induced higher Th1 responses, such as 
IgG2a isotype antibodies and IFN-γ, compared to those induced by i.m. injection (Kim et al., 
2015). In another study, stainless steel coated MNs were used to vaccinate against human 
papillomavirus and stimulated strong protective immune responses (Kines et al., 2015).  
This study aims to develop and test, for the first time, a minimally-invasive method of 
vaccination against Leishmania spp. by coating a solid MN device with a plasmid DNA cocktail 
encoding the nucleosomal histones of Leishmania infantum. The study compares the 
immunogenicity of the MN approach with conventional s.c. and i.d. injection and evaluates the 
protective capacity in BALB/c mice that have been challenged with L. major parasites. 
 
2. Material and Methods 
 
2.1. Animals and parasites 
Female BALB/c mice (Harlan, Spain) weighing approximately 20 g and aged 8 weeks were kept 
under conventional conditions, with unrestricted access to food and water. Animals were 
housed in groups of 5, in controlled environmental conditions according to ethical standards 
approved by the Animal Ethics Committee of the University of Navarra and in strict accordance 
with the relevant European legislation. 
The appropriate virulency of Leishmania major parasites (clone VI, MHOM/IL/80/Friedlin) was 
maintained by serial passages in BALB/c mice. Promastigotes were cultured in flasks at 26 °C 
in continuous stirred Schneider´s modified medium (Sigma, USA), supplemented with 20% FBS 
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and 40 mg/ml of gentamicin (Sigma, USA). L. major amastigotes were obtained from popliteal 
lymph nodes or lesions and, after transformation to the promastigote form, parasites were 
grown to the stationary phase (5-6 days) before they were used for subcutaneous murine 
inoculation at the base of the tail.  
 
2.2. Preparation of DNA plasmids and recombinant proteins 
The recombinant plasmids used in these experiments (Iborra et al., 2004) (pcDNA3-LiH2A, 
pcDNA3-LiH2B, pcDNA3-LiH3 and pcDNA3-LiH4) were obtained using the endotoxin-free Giga-
preparation Kit (Qiagen, Germany) following the manufacturer’s instructions. Purified DNA was 
re-suspended in phosphate buffered saline (PBS, Gibco, USA) and stored at – 20 °C until use. 
Expression and purification of the His-tagged recombinant proteins (pQEH2A, pQE-H2B, pQE-
H3 and pQE-H4) were performed as previously described (Iborra et al., 2004). After binding to a 
Ni-NTA agarose column (Qiagen, Germany), recombinant proteins were gradually refolded on 
the affinity column as described (Shi et al., 1997). Recombinant proteins were eluted with 0.3 or 
0.5 M imidazole (Sigma) and dialyzed against PBS. Finally, proteins were passed through a 
polymyxin-agarose column (Sigma) in order to eliminate endotoxins (endotoxin-free, less than 
30 ng/mg of recombinant protein) and kept at – 80 °C until use. 
 
2.3. Microneedle fabrication 
Solid MNs were fabricated at Cardiff School of Engineering by cutting needle structures from 
stainless steel sheets using wire electrical discharge machining (wire-EDM). The steel needles 
were then electro-polished to debur MN edges and sharpen the tips. The electro-polishing was 
carried out using a method described previously (Gill and Prausnitz, 2007). Briefly, a 300 mL 
glass beaker containing a solution of glycerol: ortho-phosphoric acid (85%): deionized water 
(6:3:1) was stirred (150 rpm) and heated to 70 °C. The cathode was connected to a copper 
plate and the anode to a MN array. Subsequently, a current density of 1.8 mA/mm2 was applied 
to each MN array for 15 minutes. MNs were cleaned by three immersions in deionized water 
and then 25% nitric acid for 30 seconds each. This was followed by another washing step in hot 
water and a final wash in deionized water. A MN applicator capable of concurrent insertion of 
three planar rows of ten MNs (30 MNs in total) was fabricated from biocompatible acrylate 
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polymer (e-Shell 200, EnvisionTEC) using an additive manufacturing technique (Zhao et al., 
2016).   
 
2.4. Imaging microneedles 
The surface morphology of MNs was imaged using a Zeiss Stemi 2000C stereomicroscope 
associated with an Olympus C3040-ADL digital camera, and was further characterized by 
scanning electron microscopy (SEM, Veeco FEI XL30, Philips). All pictures were post-
processed using ImageJ software. 
 
2.5. Coating microneedles with DNA 
MNs were visualized under the stereomicroscope throughout the coating process. A 4.5 µl (Tris-
EDTA (TE) buffer, Qiagen) solution of a plasmid DNA 60 µg cocktail containing 15 µg of each 
recombinant plasmid from L. infantum (pcDNA3-LiH2A, pcDNA3-LiH2B, pcDNA3-LiH3 and 
pcDNA3-LiH4; pHIS) was loaded into a 10 µl ultra-long tip using a 2.5 µl pipette. The plasmid 
DNA cocktail was then deposited onto three rows of ten MN arrays, using a brushing method, 
reported previously (Zhao et al., 2016), resulting in a total coating of 60 µg across 30 individual 
MNs (optimization studies, as shown in Fig. 1f, investigated application of a target dose of 10, 
20, 30 or 60 µg of DNA per 30 MNs). The same procedure was also used to coat 60 µg of non-
recombinant plasmid (4.8 µl, as negative control; pC). To determine if the coating process 
affected plasmid stability, the MN coated material was recovered in 150 µL of TE buffer. 
Aliquots from the TE buffer were then loaded into a 2% agarose gel supplemented with ethidium 
bromide and was subject to electrophoresis at 100 V for 1 h.  Coating efficiency was calculated 
by recovering the coated pDNA from the MNs, in 200 µl TE buffer, for quantitative analysis 
(NanoDrop®, ND-1000 UV-Vis Spectrophotometer; NanoDrop Technologies). 
 
2.6. DNA delivery studies 
The 30 MNs coated with 60 µg of either pcDNA3 WT (negative control, pC) or the plasmid DNA 
cocktail (pHIS) were applied directly to shaved mouse skin for 5 or 10 minutes. The delivery 
efficiency was calculated by determining the mass of DNA remaining on the MN device 
following skin insertion (NanoDrop®). 
% delivered = (calculated mass before delivery – mass post-delivery)/ (calculated mass before 
delivery) x 100 
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2.7. Visualization of fluorescence-conjugated DNA delivery into skin 
The plasmid DNA cocktail, containing Leishmania histones, was fluorescently labelled with Cy3 
(Label IT® CyTM 3 Labeling kit, Mirus Bio LLC) following the manufacturers instructions. 60 µg of 
the fluorescence-conjugated DNA cocktail was then coated on MNs that were subsequently 
inserted into shaved mouse skin for 10 minutes before the treated skin was post-stained with 
methylene blue 20% (w/v), sectioned and fixed in 4% (w/v) paraformaldehyde (Sigma) 
overnight. Samples were then washed twice with PBS for 30 minutes, embedded in OCT® 
medium and stored at – 80 °C. Skin sections of 10 µm were captured onto Superfrost Plus® 
microscope slides using a cryostat (CM3050S Leica Microsystems), dried overnight and 
observed with an OlympusBX50 light/fluorescence microscope supplied with URFL-T power 
and attached to an Olympus DP-10 digital camera. Uncoated MNs were also applied for 10 
minutes with subsequent skin staining using methylene blue (20%) to identify MN-created 
microchannels (Pearton et al., 2012). The skin samples were fixed, sectioned (10 µm) and 
stained with haematoxylin and eosin (H&E) for histological evaluation. 
 
2.8. Immunization strategies and parasite challenge 
Immunizations were carried out in groups of 10 mice with 6 different groups evaluated. The day 
before each immunization mice were anaesthetized using isoflurane and the upper back (site of 
injection) was shaved with electric clippers (Contura, Wella). Control groups (pcDNA3; pC) and 
groups receiving the DNA cocktail (pcDNA3-LiH2A, pcDNA3-LiH2B, pcDNA3-LiH3 and 
pcDNA3-LiH4; pHIS) were inoculated either s.c. or i.d., at an equivalent DNA dose derived from 
the MN delivery efficiency studies in a total volume of 30 µl sterile PBS, using 29G insulin 
needles. For the groups immunized with MNs, the coated MN arrays were mounted into the 
applicator device, manually inserted into the skin of the mice and held in place for 10 minutes. 
Mice were immunized three times at three-week intervals between each immunization. Finally, 
four weeks after the last inoculation, spleens and inguinal lymph nodes for 5 mice were 
collected for evaluation. While spleens were stimulated to detect cytokine expression, draining 
lymph nodes were immediately placed in RNA later® and stored at -20 °C for further studies. 
The remaining mice (5 mice per group) were challenged with infective 105 L. major metacyclic 
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promastigotes by s.c. injection in the base of the tail. Lesion size was monitored every week 
using a digital caliper and recorded.  
 
2.9. Determination of antibody titres and isotypes 
Blood samples for serology assessment were obtained by orbital plexus puncture eighteen days 
after the second and third immunization. Serum samples were analyzed for specific antibodies 
against Leishmania spp. histones. Briefly, high-binding ELISA plates (Greiner Bio-one) were 
coated overnight at 4 °C with 100 µL of rLiH2A, rLiH2B, rLiH3 or rLiH4 (2 µg/mL in PBS), 
respectively. In order to determine the titre, defined as the inverse of the highest serum dilution 
factor giving an absorbance > 0.2, serial dilutions of the sera were performed. The isotype-
specific analyses were done using peroxidase-labelled anti-mouse IgG1 (1:1000) or IgG2a 
(1:500) (Nordic Immunology, The Netherlands) as secondary antibodies. The peroxidase 
substrate, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid 0.01% (w/v) (ABTS, Sigma) in 
citrate buffer pH=4 and hydrogen peroxide 0.004% (v/v), was added and the absorbance was 
recorded at 405 nm after a 30 minute incubation period (iEMS Reader MS, Labsystems).   
 
2.10. Cytokine detection in supernatants of immunized mice 
Briefly, splenocyte suspensions were prepared in complete RPMI medium (RPMI 1640 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% non-essential 
aminoacids, 0.5% sodium pyruvate and 0.1% 2-mercaptoethanol). 100 µL of the suspensions 
(final concentration of 5·106 cells/mL) were seeded in 96-well plates (Corning) and stimulated for 
48 hours in the presence of the recombinant cocktail (rLiH2A+ rLiH2B+rLiH3+rLiH4, 12 µg/mL 
of each protein). Culture supernatants were harvested at – 80 °C for analysis. The release of 
several cytokines related with Th1/Th2/Treg bias was measured in the supernatants of 
splenocytes cultures by commercial ELISA Kits (BD Biosciences, USA) or Multiplex assays 
(Milliplex®, Millipore).  
 
2.11. Quantitative real-time RT-PCR 
IFN- γ, IL-4, IL-10, IL-12p35, TGF-β, iNOS, TNF-α and β-actin expression were measured in the 
draining lymph nodes of immunized mice by quantitative real time PCR using iQ SYBR Green 
supermix (Bio-Rad) and specific primers for each gene (see Table 1) in a CFX96 system from 
Bio-Rad.  
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2.12. Parasite load quantification 
Animals were euthanized fifteen weeks post-infection and livers, spleens and lymph nodes were 
aseptically excised. The number of viable parasites was calculated by PCR. 
 
2.13 Statistical analysis 
Statistical significance was analyzed using Prism 6.0 software. Differences were tested using 
the One–Way ANOVA with Dunn´s post-test for multiple comparisons. *p<0.05; **p<0.01; 
***p<0.001. 
 
3. Results 
 
3.1. Coated MNs for the delivery of plasmids into murine skin 
Stainless steel solid MNs with the same dimensions and characteristics to those used 
previously (Zhao et al., 2016) were deburred and sharpened by electropolishing (Fig. 1a and 
1b). Scanning electron microscopy (SEM) revealed that the polishing process reduced the MNs 
length from 477.1 ± 20.3 µm to 404.2 ± 29.2 µm. MN protrusions were then coated with either a 
control plasmid or the DNA cocktail (pC and pHIS, respectively). One row of ten MNs were 
coated with either 10 or 20 µg and this was then repeated in order to load 30 or 60 µg over 
three rows of ten MNs (Fig. 1c and 1d). The coating process changed the tertiary structure of 
the DNA (Fig. 1e). Before coating gel electrophoresis indicated that the pHIS mixture was in the 
supercoiled form, however after coating an additional band was detected, corresponding to 
linear DNA (upper band) (Fig. 1e). The mean coating efficiency was between 87 and 99% 
(Fig.1f). All further experiments were performed with the highest coating dose of plasmids i.e. 
60 µg  (mean mass of 58.2 ± 4.8 µg for pC and 59.3 ± 3.4 µg for pHIS coated onto MNs, which 
means a 97% and 98% coating efficiency, respectively) coated onto three arrays and 
assembled into an applicator device to enable the concurrent insertion of 30 MNs in a single 
application (Zhao et al., 2016). The dose of plasmid delivered into the mouse skin was 
dependent on the insertion time (Fig. 1g), with a greater and more reproducible delivery of both 
pC and pHIS after a 10 minute insertion time compared to a 5 minute insertion time. These 
experiments predict the dose of plasmid delivered into the skin to be approximately 50 µg for pC 
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and 55 µg for pHIS. Equivalent doses were therefore administered by conventional s.c. and i.d. 
injection.  
 
3.2. DNA delivery to ex vivo mouse skin  
To confirm successful MN insertion, MNs (uncoated) were applied to skin for 10 minutes (Fig. 
2a). Methylene blue staining was used to detect puncture sites from individual MNs (Fig. 2b). 
Histological analysis of skin sections confirmed MN insertion sites in the mouse skin. MNs 
penetrated to a depth of approximately 150 µm (Fig. 2c). Fig. 2f shows a 10 µm mouse skin 
cryosection following treatment with MNs coated with 60 µg of the fluorescently labelled-DNA 
cocktail (pHIS) (Fig. 2d). After a 10 minute insertion the majority of the pDNA was release from 
the MNs (Fig. 2e) and plasmid deposition was evident in the uppermost layers of the skin. 
 
3.3. A comparison of the immunogenicity of the L. infantum histones-DNA vaccine delivered by 
different routes 
The DNA cocktail of four plasmids encoding each one of the L. infantum core histones was 
used to immunize BALB/c mice 3 times at 3 week intervals. Three different administration routes 
were investigated, s.c., i.d. or MNs, and results were compared to a negative control. Two 
weeks after the final immunization, IgG2a-specific antibodies against H2A and H4 L. infantum 
histones were detected in the sera of mice (Fig. 3), although antibodies against H2B and H3 
were not detected. Moreover, the levels of IgG2a were greater in the group immunized with 
MNs compared to conventional i.d. injection, although the differences were not significant 
(p>0.05). Mice immunized by s.c. route did not produce any antibodies. Finally, no IgG1 
subclass anti-histone antibodies were detected.  
The cellular response induced in mice after immunization with the control DNA (pC) or the DNA 
cocktail (pHIS) was also evaluated. Four weeks after the last immunization supernatants of 
splenocytes, stimulated for 48 h with a mixture of the recombinant histone proteins, were 
harvested and analyzed. Fig. 4 indicates that MN vaccination stimulates greater immune 
responses than s.c. or conventional i.d. administration. A significant increase in IFN-γ/IL-4 ratio 
(Fig. 4a, p<0.01), IFN-γ/IL-13 ratio (Fig. 4b, p<0.01), IFN-γ/IL-10 ratio (Fig. 4c, p<0.001) and 
CXCL10 (Fig. 4e, p<0.05) and CCL2 chemokines (Fig. 4f, p<0.05) was observed after MN 
vaccination with pHIS compared to s.c. pHIS. The levels of IFN-γ/IL-4 ratio (Fig. 4a, p<0.05) and 
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the chemokine CXCL9 (Fig. 4d, p<0.05) were also significantly higher than those detected after 
conventional i.d. vaccination with pHIS. Interestingly, mice immunized with MNs coated with pC 
and pHIS had significantly higher IL-6 and IL-1β levels than mice immunized with pC via the s.c. 
route (Fig. 4g, p<0.05 and p<0.05, respectively; Fig. 4h, p<0.01 and p<0.05, respectively). 
Regarding cytokine expression in lymph nodes, a significant increase in IFN-γ/IL-4 (Fig. 5a, 
p<0.01), IFN-γ/IL-10 (Fig. 5b, p<0.05), and IFN-γ/TGF-β (Fig. 5c, p<0.05) ratios was observed 
after pHIS MN vaccination compared to pHIS vaccination using the s.c. route. Furthermore, the 
expression of iNOS (Fig. 5e) and TNF-α (Fig. 5f) was significantly increased (p<0.05) after MN 
vaccination, compared to pC administration via the s.c. route. Conversely, IL-12 levels were 
very low (data not shown) and IL-12/IL-10 ratio was comparable between all administration 
routes in both spleens (data not shown) and lymph nodes (Fig. 5d). Finally, no significant 
differences were observed between the different groups in the production of IL-2, IL-17, CCL5 
or CCL3 in the spleens (data not shown). 
 
3.4. Vaccination with the pcDNA3 cocktail, using coated MNs, does not protect mice against L. 
major challenge  
This study also evaluated whether the MN immunization strategy could provide protection 
against L. major infection in BALB/c mice. Four weeks after MN vaccination with pHIS, encoding 
the L. infantum histones mixture, mice were challenged with 105 L. major stationary 
promastigotes. There was no reduction in the size of the lesion when mice were treated with pC 
(control plasmid) administered by s.c. route or pHIS administered by MNs (Fig. 6a). In addition, 
parasite burden in spleens, livers and lymph nodes was similar in treated (MN pHIS) and control 
(s.c. pC) mice (Fig. 6b).  
 
4. Discussion 
 
Vaccination is the most important weapon for combating infectious diseases. However, as 
conventional liquid vaccine injections require trained personal, controlled storage and careful 
disposal, a number of alternative vaccine delivery technologies have received attention. Given 
their reduced dimensions, MNs significantly reduce patient pain and apprehension and, more 
importantly, accurately deposit the vaccine into the epidermis and dermis. In this context, MNs 
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could facilitate improved targeting of DCs and enhanced immunogenicity, potentially at reduced 
dose, compared against i.m., s.c. or i.d. injection using classic needle and syringe methods 
(Fehres et al., 2013). Comparative studies using MNs have demonstrated superiority over i.m. 
or i.d. vaccination in a number of applications (DeMuth et al., 2014; Hsueh et al., 2017; Kim et 
al., 2009). In this study coated MNs were used to deliver a vaccine payload in a ‘dried form’. 
This offers practical advantages in terms of stability during transport and storage, and while the 
laboratory scale manual coating process used in this study is time consuming and labor 
intensive, automated methods of MN coating provide opportunities for scale up. 
Leishmania spp. nucleosomal histones elicit interesting immune responses and have been 
investigated as potential candidate vaccines to prevent leishmaniasis (Carneiro et al., 2012; 
Carrion et al., 2008b; Iborra et al., 2004). Herein, MN administration of these histones, in the 
form of a plasmid DNA vaccine, has been explored and may result in a superior immune 
response compared to conventional i.m., s.c. or i.d. injection administration. The data presented 
suggests that the MN immunization strategy for pHIS produces an improvement in immune 
response compared to conventional delivery methods. This improvement was demonstrated in 
terms of increased Th1/Th2 cytokines ratio (IFN-γ/IL-4 and IFN-γ/IL-13 ratios) and also 
Th1/Treg ratio (IFN-γ/IL-10 and IFN-γ/TGF-β ratios) in spleens and lymph nodes (Fig. 4a-c and 
Fig. 5a-c). It is well established that IFN-γ production is fundamental for the development of a 
Th1 response. In contrast, IL-4 promotes susceptibility to infection, driving Th2 responses. 
Similarly, IL-13 might block the onset of Th1 development towards a Th2 bias. Additionally, the 
immunosuppressive IL-10, produced by Treg cells among other cells, is crucial for parasite 
survival (Kedzierski and Evans, 2014). 
TGF-β has also been shown to inhibit Th1-type immune response, leading to Leishmania spp. 
progression, by blocking IFN-γ, TNF-α and NO production (Kedzierski and Evans, 2014). This 
study showed that MN immunization with the pHIS mixture results in a cytokine profile indicative 
of a polarized Th1 immune response, which is essential for the prevention of leishmaniasis. 
However, low IL-12 production, a crucial cytokine for Th1 cell differentiation, was observed in 
spleens and lymph nodes of immunized mice (data not shown). IL-12p35/IL-10 ratio in the 
lymph nodes was also not significantly greater in the groups vaccinated with MNs (Fig. 4d). The 
modulation of the immune response towards a Th1-type was later confirmed by increased levels 
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of CXCL9, CXCL10 and CCL2 chemokines after in vitro stimulation of splenocytes with 
recombinant L. infantum histones (Fig. 4d-f). These chemokines can be down-regulated by L. 
major as an immune response evasion strategy (Guerfali et al., 2008). Furthermore, CXCL9 and 
CXCL10 are also implicated in Th1 lymphocyte migration. However, CCL2 plays an important 
role in early immunity against CL and works in synergy with IFN-γ in order to activate 
macrophages to kill Leishmania spp. parasites. CCL3 and CCL5 production in spleens of 
immunized mice was comparable between the tested groups (data not shown). CCL3 is 
associated with a Th2 dominant response whereas CCL5 function presents a critical balance 
between persistence and resistance in CL (Oghumu et al., 2010). These results also support a 
preference for a Th1 response. Moreover, the higher expression of iNOS and TNF-α in the 
lymph nodes after immunization with MNs and the plasmid DNA cocktail (Fig. 5e and 5f) also 
correlates with high Th1 lymphocyte activation as these are markers of M1 macrophage 
polarization. The generation of these cytokines by macrophages could be induced by IFN-γ 
produced by Th1 lymphocytes. However, the significantly higher levels of IL-6 and IL-1β 
secreted in the spleens after vaccination with MNs and pHIS, compared to the empty plasmid 
(pC) delivered via the s.c. route, does not support a clear Th1 response. IL-6 can act as both a 
pro-inflammatory or anti-inflammatory cytokine, being a susceptible element in CL. Several 
studies have associated IL-1β with induction of Th1 responses by activating the inflammasome 
and promoting IL-12, IFN-γ and NO production (Scott and Novais, 2016). No significant 
differences were observed in IL-2 and IL-17 in the spleens of the test groups (data not shown). 
Both cytokines have been implicated in protection or resistance against leishmaniasis (Maspi et 
al., 2016).  
Regarding antibody production, the MNs and pHIS immunization strategy produced low, 
although detectable, levels of IgG2a against H2A and H4 recombinant histones, which indicates 
a preference to a Th1 response. Other treatments did not stimulate any antibody response. 
Indeed, vaccination using DNA elicits a negligible humoral response, biasing towards cellular 
responses (Aguilar-Be et al., 2005). The humoral immune response is of reduced importance in 
the protection against Leishmania spp. parasite. Although the increased Th1/Th2 lymphocyte 
and Th1/Treg ratio indicates a predominant Th1 response, which was greater in MN vaccinated 
mice, this strategy was not able to control L. major infection in BALB/c mice. Lesion size and 
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parasite burden in spleens, livers and lymph nodes were comparable in both vaccinated and 
non-vaccinated mice (Fig. 6a and 6b). Although the immunization schedule was performed with 
nucleosomal histones obtained from L. infantum and, after that, mice were challenged with L. 
major parasites, the sequences for histones in L. infantum and L. major have high identity 
values (Iborra et al., 2004).. 
The protective efficacy of Leishmania histones administered as a DNA vaccine, either 
homologous (plasmid DNA only) or heterologous immunization (plasmid DNA + recombinant 
protein and/or adjuvant) has been previously reported against different species of Leishmania 
with contradictory results. This homologous vaccine was effective in murine models of CL 
caused by L. major (Carrion et al., 2008b; Iborra et al., 2004) and L. braziliensis (Carneiro et al., 
2012) but it was not able to control infection against VL caused by L. infantum in mice (Carrion 
et al., 2008a) or hamsters (Pereira et al., 2015). However, Baharia et al. found optimum 
prophylactic efficacy using recombinant histone proteins of L. donovani instead of L. infantum 
plasmids in those hamsters infected with L. donovani (Baharia et al., 2014). These findings 
highlight the remarkable differences in disease development and host immune response 
depending on the immunization strategy, animal model and parasite specie used in the 
experiment.  
Additionally, the route of administration may also influence the effectiveness of a vaccine. While 
in the studies cited above the plasmid DNA cocktail was administered either i.m. (Carneiro et 
al., 2012; Iborra et al., 2004; Pereira et al., 2015) or s.c. (Carrion et al., 2008a, b), i.d. 
vaccination has also been used with recombinant histone proteins of L. donovani, in 
combination with a BCG adjuvant, and conferred a high degree of protection (Baharia et al., 
2014). Results using different administration routes and homologous vs. heterologous regimens 
are therefore not comparable. The number and also the life-cycle stage of parasites inoculated 
for challenge experiments could be another explanation for the inability of the vaccine to offer 
protection. It is well-known that selective metacyclic promastigotes are highly infective but 
stationary-phase promastigotes are also highly virulent due to the presence of apoptotic 
Leishmania parasites that provide survival advantage for viable parasites, favoring evasion from 
the immune system (van Zandbergen et al., 2006). In this study, we infected immunized mice 
with L. major metacyclic promastigotes, whereas in earlier studies the same number of 
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parasites (but L. braziliensis) plus a salivary gland sonicate were inoculated in the stationary 
growth phase (Carneiro et al., 2012). In addition to using different parasite species and stages, 
we performed the challenge with 105 L. major metacyclic promastigotes compared to the lower 
doses (5·104 or 3·104 L. major stationary promastigotes) used in previous reports (Carrion et al., 
2008b; Iborra et al., 2004). This high parasite dose does not mimic the natural conditions of 
infection. Similarly, vaccination with the Leishmania spp. chimeral Q protein induced strong 
protection in dogs after challenging with 5·105 promastigotes of L. infantum (Carcelen et al., 
2009) but was unable to control infection when dogs were challenged with 5·107 L. infantum 
promastigotes (Poot et al., 2009). The anatomic site of parasite inoculation might be another 
factor that affects vaccine efficacy, just as it can determine disease severity and immune 
responses induced by infection (Baldwin et al., 2003). For challenge experiments in the current 
study, parasites were inoculated in the base of the tail. However, inoculation in the ear 
(Carneiro et al., 2012) or footpad (Carrion et al., 2008b; Iborra et al., 2004) has also been 
performed previously. The dose of vaccine administered to mice could also contribute to the 
lack of efficacy.  
In this study, we hypothesized that it was possible to obtain commensurate or greater immune 
responses using a reduced dose of DNA vaccine when it is administered via MNs since the 
device would be better than conventional injections at targeting the payload to DCs. Previous 
studies with this plasmid DNA cocktail obtained protection against Leishmania spp. infection by 
administering a dose of 80, 100 or 200 µg (Carneiro et al., 2012; Carrion et al., 2008b; Iborra et 
al., 2004). This study developed a MN device with 30 MNs (10 MNs per row) able to coat 60 µg 
of plasmid DNA (pC or pHIS). Coating optimization revealed that the entire surface of the MNs 
was coated with plasmid (Fig. 2d). Attempts to coat greater doses resulted in deposition of the 
plasmid on the base plate rather than the MN protrusions, which precludes subsequent delivery 
into the skin. The delivery studies revealed that approximately 55 µg (Fig. 1g) of the DNA 
cocktail was removed from the coated MN structures after application to the skin, which is 1.5, 2 
and 4-fold lower than that delivered in previous studies using comparable plasmids (Carneiro et 
al., 2012; Carrion et al., 2008b; Iborra et al., 2004). In this study histology indicates that MNs 
penetrated to a depth of 150-200 µm (Figure 2c). However, it is difficult to obtain accurate 
measurements for the penetration depth of MNs using traditional histology. This is partly due to 
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changes in the tissue during histology processing but most importantly due to the mechanical 
properties of the tissue and its tendency to re-seal following physical insult by the MN. Whilst 
this study demonstrates that delivery of the DNA cocktail using coated MNs was more effective 
than conventional s.c or i.d. injection in terms of improved immune response, the dose of 
vaccine delivered into the viable epidermis and dermis by the MNs may have been too low to 
confer protection. Future studies should investigate the potential of higher dosing strategies, by 
increasing the number of MN protrusions (40-50 vs. 30 MNs) or using greater MN lengths (to 
increase the coating capacity and depth of penetration). Hollow MN delivery systems may also 
offer an alternative method of delivery that has advantages in terms of dosing capacity, flexibility 
and reproducibility. These MN delivery systems are particularly suited to DNA delivery as they 
are able to improve intracellular delivery in the skin using a hydrodynamic mechanism (Dul et 
al., 2017). They are also more amenable to early clinical testing and scale up as they negate 
the complexities of MN coating and therefore future studies should investigate their potential in 
leishmaniasis pDNA immunizations. 
 
5. Conclusions 
In summary, this study highlights interesting perspectives for the prevention of leishmaniasis 
and addresses, for the first time, the use of MNs for Leishmania spp. vaccination. The reduced 
pain and ease of self-administration of MNs compared to conventional injections could be 
particularly attractive in developing countries, diminishing healthcare costs and improving 
compliance. WHO and the PATH program (Program for Appropriate Technology in Health), 
have indicated that more rigorous studies are required to compare vaccinations in terms of 
doses, routes and number of administrations. Overall, results indicate that although a MN 
administered L. infantum histones-DNA vaccine improved immunogenicity, it did not confer 
protection against L. major challenge in the susceptible BALB/c mouse model. Further studies 
using MN devices that facilitate higher plasmid loads are warranted. Furthermore, research on 
the immune mechanisms underlying the therapeutic effect of histones and the influence of type 
(homologous vs. heterologous) and regimen of immunization, administration of 
immunoadjuvants and the animal models used are critical aspects to consider in the 
development of potent vaccines against Leishmania spp.  
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Figure Captions 
Fig. 1. Light microscopy images of MNs (a) before and (b) after electropolishing. The coating 
technique, (c) and (d), used a fine pipette tip filled with 60 µg of pHIS. Gel electrophoresis of 
pHIS before and after coating (e). Percentage of pC and pHIS coated onto MNs (f). MNs were 
coated with pC and pHIS and applied to mouse skin for 5 or 10 minutes. The remaining peptide 
was dissolved off the MNs and quantified to calculate the percentage delivered into skin (g).  
Fig. 2. MN array penetration and formation of microchannels after a 10 minute application into 
mouse skin (a). Methylene blue post-staining further reveals MN puncture sites following 
microneedle application (bar=500 µm) (b). H&E stained histological section (10 µm) of mouse 
skin treated with microneedles and showing the point of microneedle penetration (bar=300 µm) 
(c).  Fluorescent images of MNs coated with the fluorescently labeled pHIS before (d) and after 
(e) a 10 minute insertion into mouse skin (bar=500 µm). Skin cryosection (10 µm) of ex vivo 
mouse skin observed by flourescence microscopy after a 10 minute application of MNs coated 
with fluorescently labelled pHIS (bar=50 µm). 
Fig. 3. Specific humoral response induced in immunized mice with the DNA cocktail or the 
control plasmid administered by s.c. route (s.c. pHIS and s.c. pC), by conventional i.d. injection 
(i.d. pHIS and i.d. pC) or using MNs (MN pHIS and MN pC). Two weeks after the last 
immunization, mice were bled and sera were tested by Elisa for anti-H2A,-H2B, -H3 and -H4 
antibody responses of both IgG1 and IgG2a isotypes. 
Fig. 4. Cytokine production by splenocytes of immunized mice either with the DNA cocktail or 
the control plasmid administered by s.c. route (s.c. pHIS and s.c. pC), by conventional i.d. 
injection (i.d. pHIS and i.d. pC) or using MNs (MN pHIS and MN pC). Mice were immunized 
three times at three-week intervals. Four weeks after the last immunization, mice were 
sacrificed. After ex vivo 48 h splenocytes stimulation with the histones cocktail, supernatants 
were collected and cytokine levels were determined by Multiplex kit. *p<0.05, **p<0.01, 
***p<0.001.  
Fig. 5. Cytokine expression in lymph nodes of immunized mice either with the DNA cocktail or 
the control plasmid administered by s.c. route (s.c. pHIS and s.c. pC), by conventional i.d. 
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injection (i.d. pHIS and i.d. pC) or using MNs (MN pHIS and MN pC). Mice were immunized 
three times at three-week intervals. Four weeks after the last immunization, mice were 
sacrificed and cytokine expression was determined by PCR. Gene expression has been 
normalized using β-actine. *p<0.05, **p<0.01.  
Figure 6: Course of L. major infection in vaccinated mice. BALB/c mice (n=5) were immunized 
either s.c with pC or by the use of MNs with pHIS (a). 4 weeks later, mice were challenged with 
infective 105 L. major metacyclic promastigotes injected by s.c. route in the base of the tail. After 
15 weeks, no differences in lesion size were observed between the two groups. The number of 
parasites in spleen, liver and lymph nodes was equivalent in vaccinated and control mice (b).  
Fig. 1 
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Fig. 5 
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Fig. 6 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
100
200
300
400
s.c.pC
MN pHIS
Weeks after infection
L
e
s
io
n
 s
iz
e
 (
m
m
2
)
Spleen Liver Lymph node
0
5.0103
1.0104
1.5104
sc pC
MN pHIS
n
u
m
b
e
r 
o
f 
c
o
p
ie
s
/n
g
 D
N
A
(a) (b)
 
 
   
 
33 
 
Table 1. Primers used for PCR analysis. 
Genes Nucleotide sequence (5´-3´) 
IFN-Υ 
TCAAGTGGCATAGATGTGGAAGAA 
TGGCTCTGCAGGATTTTCATG 
IL-4 
GCTATTGATGGGTCTCAACC 
TCTGTGGTGTTCTTGTTGC 
IL-10 
GGACAACATACTGCTAACCG 
AATCACTCTTCACCTGCTCC 
IL-12p35 
CACGCTACCTCCTCTTTTTG 
AGGCAACTCTCGTTCTTGTG 
TGF-β 
CGGCAGCTGTACATTGAC 
TCAGCTGCACTTGCAGGAGC 
TFN-α 
CTTCCAGAACTCCAGGCGGT 
GGTTTGCTACGACGTGGG 
iNOS 
TCCTACACCACACCAAACTG 
AATCTCTGCCTATCCGTCTC 
β-actin 
CGCGTCCACCCGCGAG 
CCTGGTGCCTAGGGCG 
 
 
